Cardiology Department, The Prince Charles Hospital, Brisbane, Queensland, Australia.
School of Clinical Medicine, Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Catheter Cardiovasc Interv. 2022 Oct;100(4):520-529. doi: 10.1002/ccd.30357. Epub 2022 Aug 16.
We assessed sex differences in treatment and outcomes in ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI).
Historically, delays to timely reperfusion and poorer outcomes have been described in women who suffer STEMI. However, whether these sex discrepancies still exist with contemporary STEMI treatment remains to be evaluated.
Consecutive STEMI patients treated with primary PCI patients over a 10-year period (January 1, 2010 to December 31, 2019) from a tertiary referral center were assessed. Comparisons were performed between patient's sex. Primary outcomes were 30-day and 1-year mortality. Secondary outcomes were STEMI performance measures.
Most patients (n = 950; 76%) were male. Females were on average older (66.8 vs. 61.4 years males; p < 0.001). Prehospital treatment delays did not differ between sexes (54 min [IQR: 44-65] females vs. 52 min [IQR: 43-62] males; p = 0.061). STEMI performance measures (door-to-balloon, first medical contact-to-balloon [FMCTB]) differed significantly with longer median durations in females and fewer females achieving FMCTB < 90 min (28% females vs. 39% males; p < 0.001). Women also experienced greater rates of initial radial arterial access failure (11.3% vs. 3.1%; p < 0.001). However, there were no significant sex differences in crude or adjusted mortality between sexes at 30-days (3.6% male vs. 5.1% female; p = 0.241, adjusted OR: 1.1, 95% CI: 0.5-2.2, p = 0.82) or at 1-year (4.8% male vs. 6.8% female; p = 0.190, adjusted OR: 1.0, (95% CI: 0.5-1.8; p = 0.96).
Small discrepancies between sexes in measures of timely reperfusion for STEMI still exist. No significant sex differences were observed in either 30-day or 1-year mortality.
我们评估了在接受直接经皮冠状动脉介入治疗(PCI)的 ST 段抬高型心肌梗死(STEMI)患者中,治疗和结局的性别差异。
从历史上看,女性 STEMI 患者存在延迟再灌注和预后较差的情况。然而,随着当代 STEMI 治疗的发展,这些性别差异是否仍然存在仍有待评估。
评估了一家三级转诊中心在 10 年期间(2010 年 1 月 1 日至 2019 年 12 月 31 日)接受直接 PCI 治疗的连续 STEMI 患者。对患者的性别进行了比较。主要结局是 30 天和 1 年死亡率。次要结局是 STEMI 表现指标。
大多数患者(n=950;76%)为男性。女性平均年龄较大(66.8 岁[IQR:44-65] vs. 61.4 岁男性;p<0.001)。性别的院前治疗延迟时间无差异(54 分钟 [IQR:44-62] vs. 52 分钟 [IQR:43-62] 女性;p=0.061)。STEMI 表现指标(门到球囊、首次医疗接触到球囊[FMCTB])在女性中存在明显的中位数较长,且较少女性达到 FMCTB<90 分钟(28%女性 vs. 39%男性;p<0.001)。女性也经历了更高的初始桡动脉入路失败率(11.3% vs. 3.1%;p<0.001)。然而,在 30 天(3.6%男性 vs. 5.1%女性;p=0.241,调整后的 OR:1.1,95%CI:0.5-2.2,p=0.82)或 1 年(4.8%男性 vs. 6.8%女性;p=0.190,调整后的 OR:1.0,95%CI:0.5-1.8,p=0.96)时,男女之间的死亡率在粗死亡率或调整后死亡率方面均无显著差异。
在 STEMI 的及时再灌注方面,男女之间仍然存在一些微小的差异。在 30 天或 1 年死亡率方面,没有观察到显著的性别差异。